Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Trimel Pharmaceuticals Corp

+ Add to Watchlist

3TP:GR

0.486 EUR 0.0000.00%

As of 02:00:15 ET on 05/29/2015.

Snapshot for Trimel Pharmaceuticals Corp (3TP)

Open: 0.486 Day's Range: 0.486 - 0.486 Volume: 0
Previous Close: 0.486 52wk Range: 0.213 - 0.621 1-Yr Rtn: -15.18%

Stock Chart for 3TP

No chart data available.
  • 3TP:GR 0.486
  • 1D
  • 1M
  • 1Y
0.486
Interactive 3TP Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 3TP

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.0250
Est. PEG Ratio -
Market Cap (M EUR) 97.62
Shares Outstanding (M) 200.87
30 Day Average Volume 0
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 3TP

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for 3TP

Trimel Pharmaceuticals Corp. is a pharmaceutical development company. The Company's primary objective is to exploit Trimel's drug-delivery technology portfolio and to target unmet medical needs in underserved disease states. Trimel's term objectives include the development of products for the treatment of male hypogonadism, female sexual dysfunction, and Parkinson's disease.

Tom RossiPresident/CEOKenneth G HowlingChief Financial Officer
Hubert CzerwinskiPres:Trimel Biopharma SRLNathan John BrysonVP:Scientific Affairs
More Company Profile & Key Executives for 3TP

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil